Search Medical Condition
Please enter condition
Please choose location from dropdown

Geneva 14, Switzerland Clinical Trials

A listing of Geneva 14, Switzerland clinical trials actively recruiting patients volunteers.

RESULTS

Found (221) clinical trials

Safety Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia

LDL-C = low density lipoprotein cholesterol QM = once monthly Double blind = neither the subject, the site staff nor the Sponsor study team will know whether the subject is receiving either evolocumab or placebo Open label = all subjects receive evolocumab

Phase

0.0 miles

Learn More »

Study to Evaluate the Safety of Repatha in Pregnancy

Women diagnosed with familial hypercholesterolaemia (FH), treated at centres in Europe, South Africa and Australia, with pregnancy confirmed during the study observation period and who provide informed consent to participate in the study. Exposed subjects are women who received Repatha during pregnancy and/or breastfeeding; unexposed subjects are women who have ...

Phase N/A

0.0 miles

Learn More »

Chart Review of Repatha in Subjects With Hyperlipidaemia

Review of clinical characteristics of patients who are prescribed Repatha and how their treatment is managed.

Phase N/A

0.0 miles

Learn More »

Trial to Evaluate the Safety ofTalimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab

This is a phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors with known progression alone and in combination with systemic IV administration of pembrolizumab, in subjects with non-HCC liver metastases from BC, CRC, GEC, melanoma, NSCLC, RCC, and subjects with HCC. ...

Phase

0.0 miles

Learn More »

Trial Assessing Efficacy Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders

A study to evaluate the effect of 24 weeks of subcutaneous (SC) evolocumab compared with placebo,when added to standard of care, on percent change from baseline in lowdensity lipoprotein cholesterol (LDL-C) in pediatric subjects 10 to 17 years of age with HeFH

Phase

0.0 miles

Learn More »

Effect of Low Dose Radiotherapy on Brain Amyloidosis in the Treatment of Alzheimer's Disease

Alzheimer's Disease (AD) is the most frequent neurodegenerative disease associated with dementia, with a constantly increasing prevalence associated with an aging population. Amyloid deposition is considered the first molecular event occurring in AD: as already showed in an animal model, a low-dose radiotherapy (RT) course is capable of reducing AD-associated ...

Phase N/A

0.0 miles

Learn More »

A Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

The Screening period is 28 days prior to study enrollment. This study has 2 Cohorts. Cohort Triple Negative Breast Cancer and Cohort 2: Colorectal Cancer. These cohorts will enroll in parallel. There will be a Safety Follow-up period and a Long Term Follow-up period. Drug Administration: The participants will receive ...

Phase

0.0 miles

Learn More »

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo for Newly Diagnosed Patients With Glioblastoma (GBM a Malignant Brain Cancer)

The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change). Patients will receive temozolomide plus radiation therapy. They will be compared to patients receiving Nivolumab in addition to temozolomide plus radiation therapy.

Phase

1.47 miles

Learn More »

Study to Evaluate Safety Tolerability Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

This study consist of two parts (Part 1 and Part 2). The purpose of Part 1 is to evaluate the way the body absorbs, distributes and removes the drug LCZ696. This will help determine the proper dose of LCZ696 for Part 2 of the study. The purpose for Part 2 ...

Phase

1.47 miles

Learn More »